Norge - norsk - Statens legemiddelverk

novo nordisk a/s - glukagonhydroklorid - pulver og væske til injeksjonsvæske, oppløsning - 1 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - sukkersyke - legemidler som brukes i diabetes - behandling av voksne med utilstrekkelig kontrollert av type 2 diabetes mellitus som et tillegg til diett og trening:som monoterapi når metformin er ansett som upassende på grunn av intoleranse eller kontraindikasjoner, i tillegg til andre legemidler for behandling av diabetes. for resultatene fra denne undersøkelsen med hensyn til kombinasjoner, effekter på glykemisk kontroll og kardiovaskulære hendelser, og bestandene studert, se kapittel 4. 4, 4. 5 og 5.

Den europeiske union - norsk - EMA (European Medicines Agency)

eli lilly nederland b.v. - insulin lispro - sukkersyke - legemidler som brukes i diabetes - behandling av diabetes mellitus hos voksne, ungdom og barn i alderen 1 år og over. behandling av diabetes mellitus hos voksne.

Den europeiske union - norsk - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Den europeiske union - norsk - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - obesity; overweight - antiobesity preparater, ekskl. diettprodukter - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to.

Den europeiske union - norsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Den europeiske union - norsk - EMA (European Medicines Agency)

baxter holding b.v. - insulin human (rdna) - sukkersyke - legemidler som brukes i diabetes - inpremzia is indicated for the treatment of diabetes mellitus.

Norge - norsk - Statens legemiddelverk

accord healthcare b.v. - vildagliptin - tablett - 50 mg

Norge - norsk - Statens legemiddelverk

glenmark arzneimittel gmbh - sitagliptinhydrokloridmonohydrat - tablett, filmdrasjert - 50 mg

Norge - norsk - Statens legemiddelverk

glenmark arzneimittel gmbh - sitagliptinhydrokloridmonohydrat - tablett, filmdrasjert - 25 mg